Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.800
-0.010 (-0.55%)
At close: Dec 20, 2024, 4:00 PM
1.839
+0.039 (2.18%)
After-hours: Dec 20, 2024, 7:02 PM EST
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.02M in the quarter ending September 30, 2024, a decrease of -91.45%. This brings the company's revenue in the last twelve months to $11.48M, down -66.85% year-over-year. In the year 2023, Caribou Biosciences had annual revenue of $34.48M with 148.91% growth.
Revenue (ttm)
$11.48M
Revenue Growth
-66.85%
P/S Ratio
14.07
Revenue / Employee
$72,627
Employees
158
Market Cap
162.99M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
Dec 31, 2019 | 5.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.79B |
Nutex Health | 292.00M |
Nektar Therapeutics | 93.14M |
Fennec Pharmaceuticals | 49.35M |
Nanobiotix | 45.22M |
Innate Pharma | 36.20M |
scPharmaceuticals | 30.28M |
TScan Therapeutics | 9.36M |
CRBU News
- 4 weeks ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing - Seeking Alpha
- 4 months ago - Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer - GlobeNewsWire
- 5 months ago - Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board - GlobeNewsWire
- 6 months ago - Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential - Seeking Alpha
- 7 months ago - Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 7 months ago - Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences - GlobeNewsWire
- 8 months ago - Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire